The Congress will go on until Friday November 3, 2017. If interested in discussing an opportunity please, Eczema Drug Shows Efficacy in Alopecia Areata (10/11/18), Carrying on in the tradition of JAK inhibitors, another FDA approved drug, dupilumab, has proven to be useful for the treatment of the auto-immune disease alopecia areata. Whether or not this will increase the chances of a “HairTE” product to become a success, we can’t say. The truth is, hair loss is still a bit of a mystery, said Dr. Edidiong Kaminska. New partnerships are a, Fast Track Granted To Alopecia Areata Therapy (1/24/18), Literally jumping right out of the woodwork, the company, “HCell” has announced they have been granted an orphan designation from the US FDA for their novel treatment of pediatric alopecia areata. Coincidentally, a week after I shared that video I noticed that Deion posted a new video to his own Instagram account of him going back to his clinic for another FUE hair transplant to “comeplete his comeback”, in his own words. The Daily Mail newspaper published an article today on HairClone and their banking system. Shortly after Follicle Thought ran an exclusive HairClone article last week featuring commentary from the company’s CEO Paul Kemp, the company has popped up in the British news again. Jon Knight provided this brief quote regarding the trial for readers: “, While it is disappointing to know the trial was not able to begin as planned, it is good to know that J. Hewitt is still actively working to initiate the trial. That compound is none other than RT1640 which has been featured in multiple articles on Follicle Thought for its abilities to, In the study, Hsu et al. The hair banking is a creative system, and will be very useful for patients if all goes as planned, but, it should be coupled with the therapy and not overlook it. It contains the important information which has already been listed on Follicle Thought, though it  also includes many more details. Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners. It looks like Organ Technologies’ recent announcement of its hair cloning progress has attracted some investment capital. In the research it was discovered that dermal fibroblasts. In US dollars this converts to roughly $5.3 million, still a good haul. Besides covering Yuva’s background and website information. It will be interesting to see if RCH-01 or other hair growth injectables will be tested using the RCI-01 device someday. What some may not be aware of is the fact that Dr. Denver Lough, CEO of PolarityTE, has done some legitimate hair follicle research while at Johns Hopkins University. If you’re a fan of the content here and would like to support the mission of Follicle Thought please visit, Histogen Still Optimistic For Phase 2a Trial To Begin Soon (4/27/20), Canadian Startup Seeks Combination Therapy For Hair Growth (4/22/20), New TissUse Neopapillae Paper Published (4/16/20), Today, a team of researchers from the German company TissUse published a new scientific study on the company’s hair cloning technology. Histogen. This is actually the second grant HairClone has been awarded by InnovateUK as they also received a grant back in January 2020. I’m also in favor of the fact that the Teslabrush does not replace other treatments one may be utilizing, but instead, Bernhard has said it works well with other hair growth treatments and has been shown to enhance them through combination. The announcement was made this week via press release. Breaking news headlines about Hair Loss, linking to 1,000s of sources around the world, on NewsNow: the one-stop shop for breaking news. There is more information and commentary from Bernhard on the, New BBC Documentary about Hair Loss (3/21/18 – Updated), Unfortunately, as of now the video is only available on, for people living in the UK. View, Existing Drug For Osteoporosis Holds Promise For Hair (5/9/18), New Understanding of Gray Hair Cause (5/8/18), Researchers from the NIH and the University of Alabama, Birmingham have discovered a connection between the body’s innate immune regulation and hair graying. As a reminder, this trial was designed to only evaluate the safety, tolerability, and pharmacokintetics (how the drug chemically affects the body) of KX-826, not efficacy. An increasingly common use entails using microneedling or skin puncturing for better … Or view hourly updated newsfeeds in your RSS reader: Keep up to date with the latest news from ScienceDaily via social networks: Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Lee mentioned, Yes, it seems likely that if the data is positive, Shiseido would go to market with one of the biggest technological breakthroughs of the century. The user notes that he has began dermarolling (microneedling). I just received an email sharing a new Trinov website: Happy Thanksgiving + New Article (11/22/18), Follicle Thought is interested in connecting with scientists and startups who are working on hair growth or hair loss prevention research. I was also able to conduct a brief interview with the founder of the company, Keshav Singh PhD. But it’s good news all around as YOFOTO will provide money for Replicel’s continued development. Inventage Lab Prepares Two Versions Of Slow Release Finasteride For Trials (9/28/28), According to the Korea Biomedical Review, Inventage Lab of Korea has secured a strategic partnership with Daewoong Pharmaceutical to bring two versions of finasteride encapsulated in a special delivery system to market. Women would pay an average of 40% more … I’ve started a discussion thread to talk about these things, please visit and voice your opinion ->, Aclaris’ ATI-502 Misses Goal In Clinical Trial (7/5/19), In this case, the vehicle performed in a similar range to the actual drug candidate thus the ATI-502 program for alopecia areata will be cancelled. Hair loss is normal, We can lose between 50 and 100 hairs a day, often without noticing. It’s not clear what stage of development the hair growth product is at, but it’s good to have it listed in. More info to come soon. This time, the investment comes from Allergan Aesthetics and UK based VC firm Fortunis Capital. To read the full article, New Injectable Form Of Finasteride Being Trialed (10/19/19). Leonhardt Ventures announced the discovery via. However, I was expecting the product to launch with a full data set available, and without one there’s not enough evidence to get involved. Head over to the Articles page to read more about this company’s plans for the hair industry. This announcement comes on the heels of a $7.5M investment that Stemson received from Allergan Aesthetics and Fortunis Capital, which is an investment firm based in the UK. Multiple companies are in discussion with the Koehler Lab regarding testing new hair growth compounds on cultured human hair follicles. A, We have yet another biotech research company working on a next-gen hair growth cosmetic product. While his exact findings have not been publicized to date, it would seem that he is confident in his discoveries thus far. After this Japanese content started to spread and discussion grew there has been a post on Reddit which claims Tsuji’s clinical trials were ‘already done’ in 2019. Fortunately, there are about five new therapies which have been added. As we wait and anticipate the market release of a new hair treatment there may be times when the waiting gets to us and we feel disappointed, frustrated, and even depressed. (10/4/20), Back in May 2017 media headlines were ablaze with the latest “cure for baldness discovery”, which came from the University of Texas Southwestern and was led by Dr. Lu Le. An interesting quote from Professor Koehler: “, Initially the research was aimed at treating deafness by growing tiny versions of the inner ear in vitro. HairClone Responses From Paul Kemp (8/9/19), Regarding The Latest Dr. Tsuji Talk (8/7/19), For starters, there is a Japanese Youtuber name “Youngjet” who posted a.